Leukemia Clinical Trial
Official title:
Phase II Pilot Trial to Evaluate the Efficacy of a Combined Therapy Approach for Young CLL Patients With Advanced and Progressive Disease Stratified According to the Biological Prognostic Features
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in
different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as alemtuzumab, can block cancer
growth in different ways. Some block the ability of cancer cells to grow and spread. Others
find cancer cells and help kill them or carry cancer-killing substances to them. A
peripheral stem cell transplant using stem cells from the patient or a donor may replace the
patient's immune cells that were destroyed by chemotherapy.
PURPOSE: This phase II trial is studying how well giving fludarabine together with
alemtuzumab or cyclophosphamide followed by peripheral blood stem cell transplant or
alemtuzumab works in treating patients with advanced or progressive chronic lymphocytic
leukemia.
OBJECTIVES:
Primary
- Determine the antitumor activity of induction therapy comprising fludarabine phosphate
with either alemtuzumab or cyclophosphamide followed by peripheral blood stem cell
transplantation or alemtuzumab in patients with advanced or progressive chronic
lymphocytic leukemia.
Secondary
- Determine the toxicity of this regimen in these patients.
- Determine the length of survival, event-free survival, and disease-free survival of
patients treated with this regimen.
- Evaluate the relationship between different clinical and biological disease
characteristics, therapeutic response, and survival.
OUTLINE: This is a pilot, multicenter study. Patients are stratified according to biological
risk profile (high vs low risk).
- Group 1 (high-risk patients):
- Induction therapy: Patients receive fludarabine phosphate IV and alemtuzumab IV on
days 1-3. Treatment repeats for 4 courses.
Patients with no response (no good clinical partial response, steady disease, or progressive
disease) after induction therapy are removed from the study. Other patients proceed to
post-induction therapy based on response to induction therapy.
- Post-induction therapy:
- Complete clinical, cytometric, and molecular response: Patients undergo peripheral
blood stem cell (PBSC) mobilization with cytarabine IV twice daily on days 1-3 and
filgrastim (G-CSF) followed by no further therapy.
- Response to induction therapy and evidence of residual disease (complete clinical
and cytometric response with molecular evidence of disease; complete clinical
response only; or good clinical partial response): Patients without an HLA
familial matched donor undergo PBSC mobilization with cytarabine IV twice daily on
days 1-3 and G-CSF. Patients with sufficient harvested autologous PBSCs undergo
autologous PBSC transplantation (with BEAM conditioning regimen [carmustine,
etoposide, cytarabine, and melphalan]). Patients without sufficient harvested
- PBSCs receive alemtuzumab subcutaneously (SC) weekly for 6 weeks. Patients who do
not achieve molecular remission after 6 weeks of alemtuzumab receive 6 additional
weeks of treatment. Patients with an HLA familial matched
- undergo reduced-intensity allogeneic stem cell transplantation (with
cyclophosphamide, thiotepa, and fludarabine phosphate as conditioning regimen).
- Group 2 (low-risk patients):
- Induction therapy: Patients receive fludarabine phosphate and cyclophosphamide on days
1-3. Treatment repeats every month for 4 courses. Patients achieving at least a partial
response receive 2 additional courses.
Patients achieving complete clinical response with cytometric and molecular response;
complete clinical response with a cytometric response; or complete clinical response after
completion of induction therapy (i.e., partial response or greater) receive no further
treatment. Patients with no response or disease progression proceed to post-induction
therapy.
- Post-induction therapy: Patients receive alemtuzumab SC weekly for 6 weeks. Patients
who do not achieve complete remission after 6 weeks of alemtuzumab receive 6 additional
weeks of treatment.
PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |